Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Nov 2, 2011Multi-center study published in Gastrointestinal Endoscopy is largest ever reported on peroral cholangioscopy
Boston Scientific Corporation (NYSE: BSX) welcomes study results published in the October issue of Gastrointestinal Endoscopy showing an overall...
-
Nov 1, 2011Clinical presentations to include 12-month data on fourth-generation SYNERGY™ Stent
Boston Scientific Corporation (NYSE: BSX) releases the schedule of its major events and product-related clinical research for the Cardiovascular...
-
Oct 27, 2011Video demonstration of CardioTeach™ app by Dr. Kenneth Stein available online
Boston Scientific Corporation (NYSE: BSX) introduces its CardioTeach™ iPad® app, an industry-first, free educational resource to help healthcare...
-
Oct 20, 2011
Boston Scientific Corporation (NYSE: BSX) announces financial results for the third quarter ended September 30, 2011, as well as updated sales and...
-
Oct 18, 2011
Boston Scientific Corporation (NYSE: BSX) has completed enrollment in a clinical trial to evaluate its WallFlex® Biliary RX Fully Covered Stent for...
-
Oct 17, 2011Company's everolimus-eluting platinum chromium stent now being marketed in world's second-largest DES market
Boston Scientific Corporation (NYSE: BSX) has begun a phased launch of its PROMUS Element™ Everolimus-Eluting Platinum Chromium Coronary Stent System...
-
Oct 14, 2011
Boston Scientific Corporation (NYSE: BSX) welcomes yesterday's introduction of the Medical Device Regulatory Improvement Act, sponsored by Sen. Amy...
-
Oct 11, 2011
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the third quarter ended September 30, 2011...
-
Oct 5, 2011Third-generation bare-metal stent designed to offer improved acute performance in treating patients with coronary artery disease
Boston Scientific Corporation (NYSE: BSX) has started patient enrollment in the OMEGA clinical trial, designed to evaluate the safety and effectiveness...
-
Sep 29, 2011Study designed to assess preliminary safety and efficacy of chronic vagal nerve stimulation in heart failure patients
Boston Scientific Corporation (NYSE: BSX) has enrolled the first patients in its NECTAR-HF (NEural Cardiac TherApy foR Heart Failure) clinical trial....